Lesabelimab (anti-PD-L1) - Primary antibody, specific to CD274, Human IgG1
Specifications & Purity
RUO, ≥95%(SDS-PAGE&SEC), Lot by Lot
Specificity
CD274
Conjugation
Unconjugated
Grade
RUO
Product Description
Lesabelimab (anti-PD-L1) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor. Purity ≥95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
25.8 kDa (Light Chain) & 49.1 kDa (Heavy Chain), under reducing conditions; 195.9 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2475402-56-1
Images
Lesabelimab (anti-PD-L1) (Ab182969) - Flow Cytometry Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated Jurkat cells (24h) labelling PD-L1 (red) with Lesabelimab (anti-PD-L1) (Ab182969). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Lesabelimab (anti-PD-L1) (Ab182969) - ELISA Immobilized Recombinant Human PD-L1 protein (rp169666) at 1.0 μg/mL can bind Lesabelimab (anti-PD-L1) (Ab182969) with the EC₅₀ of 172.4 ng/mL.
Lesabelimab (anti-PD-L1) (Ab182969) - SEC The purity of Lesabelimab (anti-PD-L1) (Ab182969) is more than 95% verified by HPLC.
Associated Targets
CD274Tclin Programmed cell death 1 ligand 1 0 Activities
ZJ24F0606995